Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QSI
Strong SellSinkerQuantum-Si incorporated · Healthcare · United States · $171M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Quantum-Si incorporated develops a next-generation protein sequencing platform, aiming to revolutionize proteomics research and drug discovery. Its proprietary semiconductor chip-based technology enables single-molecule protein sequencing, offering unprecedented insights into protein biology. This innovative approach positions Quantum-Si as a potential disruptor in the life sciences tools market, providing a distinct technological moat in an emerging high-growth area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.1M | 3.1M | 2.4M | 50.0% | 1.6M | 1.1M | 5.8M | 54.3% |
| EPS | -0.95 | -0.68 | -0.71 | -0.51 | — | -0.46 | -0.40 | -0.35 | — |
| Shares | 139.9M | 141.8M | 166.9M | 216.4M | +54.6% | 198.9M | — | — | — |
| Debt | 17.4M | 15.3M | 12.9M | 4.2M | -38.0% | 3.3M | — | — | — |
| Equity | 358.7M | 271.6M | 215.4M | 220.2M | -15.0% | — | — | — | — |
| Op CF | -90.6M | -94.0M | -87.8M | -94.7M | — | -92.4M | — | — | — |
| Inv CF | 137.2M | 143.4M | -32.7M | -28.3M | — | — | — | — | — |
| Fin CF | 1.9M | 0.1M | 35.9M | 95.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QSI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QSI | Quantum-Si incorporated(you) | $171M | 11 | Strong Sell |
| OWLT | Owlet, Inc. | $146M | 15 | Strong Sell |
| EBR.AX | EBR Systems, Inc. | $148M | 5 | Strong Sell |
| QTRX | Quanterix Corporation | $125M | 14 | Strong Sell |
| PAIN.V | Vector Science and Therapeutics Corp. | $233M | 8 | Strong Sell |
| LUCD | Lucid Diagnostics Inc. | $189M | 4 | Strong Sell |
| APYX | Apyx Medical Corporation | $130M | 18 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 13 | Strong Sell |
| HYPR | Hyperfine, Inc. | $88M | 12 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%